Seroatlas · Human Serome Atlas

BST2

Bone marrow stromal antigen 2

Also known as: BST-2, BST2_HUMAN, CD317, HM1.24, tetherin

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q10589
Gene
BST2
Ensembl
ENSG00000130303
Chromosome
19
Canonical length
180 aa
Protein class
CD markers, Plasma proteins, Predicted membrane proteins, Transporters
Subcellular location
Golgi apparatus,Vesicles
Quaternary structure
Homotetramer

OverviewNCBI Gene

Bone marrow stromal cells are involved in the growth and development of B-cells. The specific function of the protein encoded by the bone marrow stromal cell antigen 2 is undetermined; however, this protein may play a role in pre-B-cell growth and in rheumatoid arthritis. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

180 residues, UniProt reviewed canonical sequence.

>Q10589|BST2
     1  MASTSYDYCR VPMEDGDKRC KLLLGIGILV LLIIVILGVP LIIFTIKANS EACRDGLRAV
    61  MECRNVTHLL QQELTEAQKG FQDVEAQAAT CNHTVMALMA SLDAEKAQGQ KKVEELEGEI
   121  TTLNHKLQDA SAEVERLRRE NQVLSVRIAD KKYYPSSQDS SSAAAPQLLI VLLGLSALLQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BST2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.54
Highest tissue expression
677 nTPM

Expression across tissuesHPA

Tissue

  • ovary: 677 nTPM
  • adrenal gland: 501 nTPM
  • fallopian tube: 254 nTPM
  • spleen: 233 nTPM
  • liver: 221 nTPM
  • adipose tissue: 219 nTPM

Single-cell type

  • ovarian stromal cells: 1,149 nCPM
  • hofbauer cells: 528 nCPM
  • granulosa cells: 403 nCPM
  • peritubular myoid cells: 349 nCPM
  • vascular endothelial cells: 337 nCPM
  • medullary thymic epithelial cells: 310 nCPM

Immune cell

  • plasmacytoid DC: 423 nTPM
  • intermediate monocyte: 386 nTPM
  • total PBMC: 368 nTPM
  • non-classical monocyte: 361 nTPM
  • NK-cell: 354 nTPM
  • classical monocyte: 346 nTPM

Brain region

  • medulla oblongata: 58 nTPM
  • spinal cord: 48 nTPM
  • thalamus: 35 nTPM
  • white matter: 35 nTPM
  • pons: 29 nTPM
  • basal ganglia: 27 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about BST2.

Disease | ImmuneIEDB

Conditions an epitope on BST2 was assayed in.

ReferencesPubMed · IEDB

Publications for BST2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.41
gnomAD pLI
0
gnomAD missense Z
0.71
DepMap mean gene effect
-0.03
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

  • Bone marrow stromal antigen 2
  • Bone marrow stromal antigen 2

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of BST2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BST2 as an antibody target. Whether an autoantibody or antibody against BST2 could matter depends on whether native BST2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BST2 is annotated at the cell surface, where native BST2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label BST2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/BST2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...